COVID-19, immunocompromised host, dual anti-SARS-CoV-2 therapies, combination therapy, prolonged viral shedding, individualized therapeutic approaches
immune check point inhibition (ICI), head and neck sqamous cell carcinoma (HNSCC), CD103+ tissue-resident T cells